ojemda
Generic: tovorafenib
ojemda: sourced relationships with 2 companies.
ojemda evidence translation
What we can confirm
No verified FDA or trial count is available.
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Evidence is limited; missing information remains unknown.
BioSniper AIPage evidence connected
Prepared research question
What is verified about ojemda, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutationrelapsed or progressive pediatric low-grade glioma
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) Relapsed or refractory pediatric low-grade glioma (pLGG) har… | Approved |
| XOMA Royalty Corporation (XOMA) relapsed or progressive pediatric low-grade glioma | Approved |